Quick Project Snapshot
Presynaptic dysfunction in Parkinson’s disease
Parkinson’s Disease (PD) is the second most common neurodegenerative disorder, affecting 7 million people worldwide. The cause of PD is unknown. It is primarily a disease of ageing, affecting 1% of the population over the age of 60; this translates to 1 in 350 people in Australia living with PD. PD already costs the Australian health system almost $0.5 billion annually; with our ageing population, we can expect to incur an increasing health burden from PD. Considering the debilitating nature of this disorder, and the burden it poses to our healthcare system, it is imperative that the underlying cause of PD is identified so that therapeutics can be developed.
PD has a complex pathophysiology. Whilst there is no doubt that Lewy body formation and neuronal cell loss are end-points in PD, there is increasing evidence that disturbance in the nerve terminal precedes and possibly initiates the subsequent pathology in cell bodies. One of the earliest documented changes in both animal models of PD, as well as in patients, is synaptic dysfunction and/or loss.
Whilst the underlying cause of PD is unknown, the presynaptic protein alpha synuclein has been clearly implicated in the aetiology of the disorder. Much work has focussed on how aggregation of the protein contributes to neuronal toxicity. However, remarkably little is known about the normal physiological function of this disease-associated protein.
Several projects are on offer to examine the molecular mechanisms underlying the presynaptic functions of alpha synuclein. These projects will implement a variety of techniques, including molecular biology, biochemistry, primary neuronal cell culture from transgenic and wild-type rodent lines, fixed immunofluorescence imaging and live-cell fluorescent imaging, giving students the opportunity to master a range of key transferrable skills.
Project 1) Investigate how alpha synuclein regulates the synaptic vesicle cycle and neurotransmitter release: Alpha synuclein has been proposed to modulate various aspects of the synaptic vesicle cycle. Importantly, it controls the presynaptic targeting of a key synaptic vesicle protein, synaptobrevin II, which is crucial for neurotransmitter release. This project will determine how alpha synuclein regulates the localisation and function of synaptobrevin II and the implications this has for synaptic vesicle dynamics and neurotransmitter release.
Project 2) Investigate how phosphorylation controls the function of alpha synuclein at nerve terminals: We have recently identified novel sites in alpha synuclein that are phosphorylated in an activity-dependent manner. This project will ascertain how phosphorylation at these distinct residues modulates the function of alpha synuclein as a regulator of presynaptic activity.
All Projects by this LabPresynaptic dysfunction in Parkinson’s diseasePresynaptic dysfunction in neurodevelopmental disorders
Dr Lachlan Thompson
Prof David Finkelstein
Scientists in the Neurodegeneration division interrogate how neurones live, die and can be rescued to improve brain function in degenerative conditions such as Parkinson’s and Motor Neuron Diseases. There is no effective treatment for Motor Neurone Disease and the incidence of Parkinson’s Disease is rising alarmingly in our aging community. Gene abnormalities, energy deprivation, toxic rubbish accumulation and inflammation all contribute to a toxic environment for brain cells. Our teams study these events in animal models and cultured cells, with a view to translating knowledge into new therapies for human patients.